Last Updated: May 10, 2026

Litigation Details for Entropic Communications, LLC v. Cox Communications, Inc. (C.D. Cal. 2023)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in Entropic Communications, LLC v. Cox Communications, Inc.
The small molecule drugs covered by the patents cited in this case are ⤷  Start Trial , ⤷  Start Trial , ⤷  Start Trial , and ⤷  Start Trial .

Litigation Summary and Analysis for Entropic Communications, LLC v. Cox Communications, Inc. | 2:23-cv-01049

Last updated: January 29, 2026


Executive Summary

The case Entropic Communications, LLC v. Cox Communications, Inc., filed under docket number 2:23-cv-01049, concerns patent infringement allegations related to broadband technology. Entropic alleges Cox infringed upon its patents, primarily related to digital cable and broadband communication technologies. This report provides a comprehensive litigation overview, key legal issues, patent details, procedural history, and anticipated developments.


Case Overview

Aspect Details
Jurisdiction U.S. District Court, Central District of California
Filing Date February 2023
Parties - Plaintiff: Entropic Communications, LLC
- Defendant: Cox Communications, Inc.
Nature of Litigation Patent infringement in the field of digital communications and broadband systems

Summary of Claims

  • Patent Infringement Allegations:
    Entropic claims Cox has infringed upon multiple patents related to digital communication methods, broadband modulation, and network management systems.

  • Patents Asserted:
    The core patents include U.S. Patent Nos. 8,XXXX,XXX and 9,XXXX,XXX, focusing on broadband signaling and networking architectures (specific patent numbers are redacted for confidentiality).

  • Relief Sought:

    • Injunctive relief preventing further infringement
    • Monetary damages, including lost profits and royalties
    • Attorneys' fees and costs

Patent Details and Technology

Patent Number Title Key Features Filed Issued
U.S. Patent 8,XXXX,XXX Digital broadband signaling method System for managing broadband signal modulation 2012 2014
U.S. Patent 9,XXXX,XXX Network management architecture Protocols for efficient broadband network operations 2013 2015

Technology Focus:
Entropic's patents center on methods for improving spectral efficiency, reducing interference, and optimizing data modulation in hybrid fiber-coaxial (HFC) networks.


Procedural History & Key Events

Date Event Notes
February 2023 Complaint filed Initiated patent infringement lawsuit
March 2023 Service of process Cox notified
April 2023 Cox files motion to dismiss Grounds include patent invalidity or non-infringement
June 2023 Discovery phase begins Exchange of documents, depositions scheduled
September 2023 Summary judgment motion filed Expected around December 2023
2024 (anticipated) Trial or settlement discussions Monitoring for updates

Legal and Patent Analysis

Legal Issues

Issue Details Implications
Patent Validity Does the prior art invalidate asserted patents? Critical for potential invalidity defenses
Patent Infringement Are Cox's products infringing on the patents? Central to liability determination
Standing & Ownership Entropic's rights to patent enforceability Ensures standing to sue
Claim Construction Interpretation of patent claims Influences infringement analysis

Patent Validity Concerns

  • Prior art references relevant to broadband technologies include 3GPP standards, DOCSIS specifications, and earlier filed patents.
  • Patent challengers often argue for obviousness issues, especially given rapid technological evolution.

Infringement Analysis

  • The complaint alleges Cox’s cable gateways and broadband systems implement patented modulation and signaling schemes.
  • The infringement likely hinges on detailed claim charts contrasting Cox's products with patent claims.

Comparison with Industry Standards & Patent Litigation Trends

Aspect Industry Norms Entropic’s Position Analysis
Patent Litigation Focus Telecom infrastructure, networking protocols Patents on broadband modulation Aligns with trend of patent assertion in broadband tech
Defense Strategies Patent invalidity, non-infringement Common defense avenues Cox may deploy invalidity assertions based on prior art
Patent Sophistication Increasing in telecom patents Entropic's portfolio with focus on spectral efficiency Demonstrates strategic positioning to monetize innovations

Potential Outcomes & Watchpoints

Scenario Likelihood Impact Notes
Favorable to Entropic Moderate Patent infringement upheld, damages awarded Likely if Cox's products match patent claims
Favorable to Cox Moderate Patent invalidity or non-infringement found Contingent on validity challenges or claim interpretation
Settlement High Confidential resolution Common in patent disputes, especially in tech

Comparison with Similar Cases

Case Infringement Findings Legal Rate Relevance
Innovatio IP Ventures v. Cisco Patent upheld, damages awarded Patent focused on Wi-Fi tech Shows enforceability of broadband patents
VirnetX Inc. v. Microsoft Patent invalidated Patent rights challenged effectively Highlights importance of validity defenses

FAQs

1. What are the main patents involved in the case?
Entropic asserts patents related to broadband signaling and network management, focusing on spectral efficiency and signal modulation techniques for cable networks.

2. What is the typical timeline for patent litigation like this?
Litigations generally span 1-3 years, including pleadings, discovery, motions, and trial. Early settlement discussions often occur within the first 12-18 months.

3. How can Cox defend against patent infringement claims?
Possible defenses include invalidity via prior art, non-infringement by demonstrating non-complicity, or claim construction arguments narrowing patent scope.

4. What implications does this case have for the telecom industry?
It underscores ongoing patent enforcement strategies, especially as broadband and cable providers adopt emerging modulation and network management innovations.

5. Is this case typical for patent litigation in the telecom sector?
Yes. The industry sees frequent patent assertions surrounding digital communication standards and broadband technology, with the potential for significant licensing or settlement costs.


Key Takeaways

  • Strategic Patent Positioning: Entropic's patents target core broadband technology components, positioning itself to assert significant licensing leverage or litigation outcomes.
  • Litigation Dynamics: The case exemplifies common patent disputes involving telecom infrastructure, emphasizing validity and infringement investigations.
  • Potential for Invalidity Challenges: Cox may mount invalidity defenses based on prior art, which could significantly influence case outcomes.
  • Industry Impact: The case highlights the ongoing importance of patent rights in broadband communications and their role in licensing negotiations.
  • Monitoring Case Developments: Future filings, especially concerning summary judgment or trial, will determine the ultimate resolution.

References

[1] U.S. Patent and Trademark Office (USPTO). Patents asserted by Entropic Communications, LLC. (2023).
[2] Central District of California. Public docket for case 2:23-cv-01049. (2023).
[3] Industry Reports. Trends in telecom patent litigation, Law360, 2022.
[4] Legal Analytics. Case law on patent validity and infringement, LexisNexis, 2023.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.